Summary:
Pursuant to the Executive Order titled Delivering Most- Favored-Nation Prescription Drug Pricing to American Patients, USTR invites comments from interested parties regarding any act, policy, or practice that may be unreasonable or discriminatory and that has the effect of forcing American patients to pay for a disproportionate amount of global pharmaceutical research and development, including by suppressing the price of pharmaceutical products below fair market value in foreign countries.